Skip to main content Skip to section navigation Skip to footer
  • About Us
      Company Overview
      Team
      Careers
  • Gene Therapies
      Our Approach
      Publications & Presentations
  • Patients
      Patients & Families
      Patient Spotlight
  • Pipeline & Programs
      OPGx-BEST1
      OPGx-LCA5
      Preclinical
  • Investors
  • Contact Us
Skip to main content Skip to section navigation Skip to footer
Opus Genetics, Inc. IR Overview
  • Overview
  • Press Releases
  • Events
  • Presentations
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Financial Info
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote & Chart
    • Historical Data
    • Analyst Coverage
  • Governance
    • Overview
    • Leadership Team
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Resources
    • IR Contact
    • Email Alerts
    • Investor FAQs
    • RSS News Feed
  • Back to Corporate Site

Press Releases

Investors

  • Overview
  • Press Releases
  • Events
  • Presentations
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Financial Info
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote & Chart
    • Historical Data
    • Analyst Coverage
  • Governance
    • Overview
    • Leadership Team
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Resources
    • IR Contact
    • Email Alerts
    • Investor FAQs
    • RSS News Feed
Dec 30, 2020 8:30 am EST
Ocuphire to Present at the LifeSci Partners 10th Annual Healthcare Corporate Access Event in Early January 2021
Dec 8, 2020 7:00 am EST
Ocuphire to be Featured in Cantor Fitzgerald Fireside Chat with Equity Research Analyst Kristen Kluska
Nov 19, 2020 7:00 am EST
Ocuphire Pharma Announces First Patient Enrolled in MIRA-2 Phase 3 Clinical Trial Investigating Nyxol® for Reversal of Mydriasis
Nov 16, 2020 6:00 am EST
Ocuphire Pharma Announces Expansion of Global Patents for Nyxol® and $1.7 Million NIH Grants for APX3330 Program
Nov 12, 2020 6:00 am EST
Ocuphire Pharma Announces Two Publications Supporting the APX3330 Program
Nov 10, 2020 10:09 am EST
Ocuphire to Participate in Upcoming Virtual HCW Conference in November
Nov 6, 2020 6:00 am EST
Industry Veteran Susan Benton Joins the Ocuphire Pharma Board of Directors
Nov 5, 2020 8:33 pm EST
Ocuphire Pharma Completes Transactions and Begins Trading on Nasdaq as OCUP
Nov 5, 2020 11:50 am EST
Rexahn Pharmaceuticals Announces Expected Effectiveness of Reverse Stock Split and Merger Transaction with Ocuphire Pharma
Nov 3, 2020 8:40 am EST
Ocuphire Pharma to Host Key Opinion Leader Event on Nyxol® and APX3330
  • Previous Pagearrow_back
  • Page 1
  • …
  • Page 14
  • Page 15
  • Page 16
  • Page 17
  • Page 18
  • Page 19
  • Page 20
  • Page 21
  • Page 22
  • Page 23
  • Next Pagearrow_forward
rss_feed News RSS
  • location_cityCompany Profile
  • contact_pageContacts
  • rss_feedRSS News Feed
  • accessibilityAccessibility Statement
Opus Genetics, Inc. home Opus Genetics on LinkedIn

Sign up to receive our newsletter

By providing your email address, you consent to receive messages from Opus Genetics. View our Privacy Policy.

  • Gene Therapies
  • Patients & Families
  • Pipeline
  • About Us
  • Careers
  • Contact Us
  • Investors
© 2026 Opus Genetics, Inc.
  • Cookie Policy
  • Privacy Statement
Site by BKW